WithdrawnNot Applicable

Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer

Stopped: The principal investigator Dr.YinLi is working in other Hospital

China0Started 2017-03-21

Plain-language summary

The goal of this clinical research study is to explore whether intrathoracic hyperthermic perfusion after radical surgery could reduce local recurrence rate(13%) for advanced lung cancer / esophageal cancer. The safety of intrathoracic hyperthermic perfusion right after surgery.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must not have received any prior anticancer therapy of cancer.
✓. expected R0 resection.
✓. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of T3-4, any N and any T, N1. (8th Union for International Cancer Control, Union for International Cancer Control(UICC)-TNM). Histologic diagnosis of non small cell lung cancer, T2-T3, any N. (8th Union for International Cancer Control, UICC-TNM)
✓. Age ranges from 18 to 80 years.
✓. Without operative contraindication.
✓. Eastern Cooperative Oncology Group (ECOG) 0～2.
✓. Signed informed consent document on file.

Exclusion criteria

✕. Multiple primary cancer.
✕. The subject cannot understand and sign the informed consent form(ICF).
✕. Patients with concomitant hemorrhagic disease.
✕. Any un expected reason for patients can't get operation.
✕. Pregnant or breast feeding.

What they're measuring

local recurrent rate

Timeframe: 3 years after surgery

Trial details

NCT IDNCT03110939

SponsorHenan Cancer Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2019-04-05

View on ClinicalTrials.gov More Esophageal Cancer trials